[go: up one dir, main page]

WO1991008795A3 - Procede ameliore d'administration d'un medicament par iontophorese - Google Patents

Procede ameliore d'administration d'un medicament par iontophorese

Info

Publication number
WO1991008795A3
WO1991008795A3 PCT/US1990/007273 US9007273W WO9108795A3 WO 1991008795 A3 WO1991008795 A3 WO 1991008795A3 US 9007273 W US9007273 W US 9007273W WO 9108795 A3 WO9108795 A3 WO 9108795A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
delivery method
iontophoretic delivery
improved iontophoretic
delivering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1990/007273
Other languages
English (en)
Other versions
WO1991008795A2 (fr
Inventor
Ronald P Haak
J Richard Gyory
Jane Yieh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of WO1991008795A2 publication Critical patent/WO1991008795A2/fr
Publication of WO1991008795A3 publication Critical patent/WO1991008795A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Electrotherapy Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

Le procédé amélioré décrit utilise l'iontophorèse pour administrer à un patient un médicament ou un agent bénéfique par voie transdermique. Ce procédé consiste à sélectionner et à administrer par iontophorèse le médicament à travers un site (11) de la peau choisi de façon à optimiser la vitesse de passage transdermique du médicament, tout en réduisant au minimum les variations de résistance de la peau dues à des facteurs propres au patient.
PCT/US1990/007273 1989-12-14 1990-12-10 Procede ameliore d'administration d'un medicament par iontophorese Ceased WO1991008795A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/452,136 US5167616A (en) 1989-12-14 1989-12-14 Iontophoretic delivery method
US452,136 1989-12-14

Publications (2)

Publication Number Publication Date
WO1991008795A2 WO1991008795A2 (fr) 1991-06-27
WO1991008795A3 true WO1991008795A3 (fr) 1991-07-25

Family

ID=23795191

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/007273 Ceased WO1991008795A2 (fr) 1989-12-14 1990-12-10 Procede ameliore d'administration d'un medicament par iontophorese

Country Status (7)

Country Link
US (1) US5167616A (fr)
AU (1) AU6972591A (fr)
CA (1) CA2031873A1 (fr)
IE (1) IE904437A1 (fr)
PT (1) PT96151A (fr)
WO (1) WO1991008795A2 (fr)
ZA (1) ZA909893B (fr)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2865422B2 (ja) * 1989-10-23 1999-03-08 セラテック，インコーポレイテッド イオン浸透療法装置および速度調整膜を用いた方法
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
JPH06505712A (ja) * 1990-11-28 1994-06-30 サノ・コーポレーシヨン タバコ中毒の処理方法および装置
US5221254A (en) * 1991-04-02 1993-06-22 Alza Corporation Method for reducing sensation in iontophoretic drug delivery
US5464387A (en) * 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
US5246417A (en) * 1991-12-11 1993-09-21 Alza Corporation Indicator for iontophoresis system
ES2120477T3 (es) * 1992-01-21 1998-11-01 Macrochem Corp Administracion iontoforetica de medicamentos perfeccionada.
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5508262A (en) * 1993-12-15 1996-04-16 University Of South Florida Interleukin-1 receptor antagonist decreases severity of acute pancreatitis
US5837281A (en) * 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
US5700481A (en) * 1995-03-17 1997-12-23 Takeda Chemical Industries, Ltd. Transdermal drug delivery process
US5855867A (en) * 1995-03-29 1999-01-05 The Curators Of The University Of Missouri Hydroxymethyl phosphine compounds for use as diagnostic and therapeutic pharmaceuticals and method of making same
US6881208B1 (en) * 1995-06-05 2005-04-19 Joseph B. Phipps Method and device for transdermal electrotransport delivery of fentanyl and sufentanil
IE960375A1 (en) * 1995-06-05 1996-12-11 Alza Corp Device for transdermal electrotransport delivery of fentanyl¹and sufentanil
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
US5767084A (en) * 1995-10-06 1998-06-16 The Curators Of The University Of Missouri Method of treatment for cystic fibrosis and peptides for same
US6218594B1 (en) 1995-11-08 2001-04-17 University Of South Florida Guinea pig model for leiomyomas
US5779661A (en) * 1995-12-11 1998-07-14 Physion, S.R.L. Method of treating dysfunctional bladder syndromes by electromotive drug administration
AU3404197A (en) * 1996-06-19 1998-01-07 Becton Dickinson & Company Iontophoretic delivery of cell adhesion inhibitors
US5906976A (en) * 1996-10-22 1999-05-25 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Method and composition for treating neuronal degeneration
US5976547A (en) * 1997-04-22 1999-11-02 Niblick Pharmaceuticals, Inc. Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery
EP1030560B1 (fr) 1997-10-09 2007-09-26 Emory University Procede et dispositif d'administration transdermique du lithium
AU1375199A (en) * 1997-11-12 1999-05-31 Alza Corporation Method for decreasing self-association of polypeptides
US6489306B2 (en) 1998-02-23 2002-12-03 University Of South Florida Method of intranasal gene transfer for protection against respiratory infection
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
US6338834B1 (en) 1998-04-30 2002-01-15 The Curators Of The University Of Missouri Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
WO2000002561A1 (fr) 1998-07-13 2000-01-20 University Of South Florida Modulation de la voie de phospholipase a2 utilisee comme procede therapeutique
AU5329599A (en) * 1998-07-30 2000-02-21 University Of South Florida Method for the modulation of function of transcription factors
US6780397B2 (en) 1998-09-01 2004-08-24 Curators Of The University Of Missouri Biomolecule conjugation strategy using novel water-soluble phosphine-based chelating agents
US6638974B1 (en) 1999-04-09 2003-10-28 University Of South Florida Ascorbyl esters for the treatment of cancer
US6787318B1 (en) 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US7655423B2 (en) * 1999-06-14 2010-02-02 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
ATE408402T1 (de) * 1999-06-14 2008-10-15 Ford Henry Health System Stickstoffmonoxid-donoren zum induzieren von neurogenese
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
US6462066B2 (en) 1999-12-02 2002-10-08 University Of South Florida Method and composition for treatment of ischemic neuronal reperfusion injury
AU2002218744A1 (en) * 2000-07-11 2002-01-21 University Of South Florida Bax fragment induced tumor cell death
US6803060B2 (en) 2000-09-07 2004-10-12 Joe Reyes Composition to boost libido
WO2002034119A2 (fr) * 2000-10-27 2002-05-02 Immuno-Rx, Inc. Immunotherapie vaccinale pour patients immunodeprimes
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US7182942B2 (en) * 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
EP1810691A3 (fr) 2001-10-26 2008-03-26 IRX Therapeutics, Inc. Immunothérapie pour inverser une suppression immune
EP1556061B1 (fr) * 2002-10-04 2007-04-18 Photokinetix Inc Delivrance photocinetique de substances biologiquement actives au moyen d'une lumiere incoherente pulsee
AU2003284968A1 (en) * 2002-10-25 2004-05-13 University Of South Florida Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
US7220778B2 (en) * 2003-04-15 2007-05-22 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
WO2005021065A2 (fr) * 2003-08-29 2005-03-10 New York University Administration indirecte de facteurs de croissance dans le systeme nerveux central
WO2005034980A1 (fr) * 2003-09-12 2005-04-21 University Of Colorado Glutamine pour le traitement de lesion
WO2005059100A2 (fr) * 2003-12-12 2005-06-30 New York University Procedes et compositions se rapportant a la cystatine c
CA2550943A1 (fr) * 2003-12-30 2005-07-14 Syndrome X Ltd. Procede d'administration d'acide 3,3,14,14 tetramethyl hexadecane 1,16 dioique
JP4755113B2 (ja) 2004-01-30 2011-08-24 クアーク・ファーマスーティカルス、インコーポレイテッド 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
DK2319925T3 (da) 2004-08-16 2018-11-05 Quark Pharmaceuticals Inc Terapeutiske anvendelser af RTP801-hæmmere
PT1799269T (pt) 2004-09-28 2016-10-04 Quark Pharmaceuticals Inc Oligorribonucleótidos e métodos para uso dos mesmos para o tratamento da alopecia, insuficiência renal aguda e outras doenças
US8386030B2 (en) 2005-08-08 2013-02-26 Tti Ellebeau, Inc. Iontophoresis device
US8295922B2 (en) 2005-08-08 2012-10-23 Tti Ellebeau, Inc. Iontophoresis device
US20070088331A1 (en) * 2005-08-18 2007-04-19 Transcutaneous Technologies Inc. Method and apparatus for managing active agent usage, and active agent injecting device
RU2008114490A (ru) 2005-09-15 2009-10-20 ТиТиАй ЭЛЛЕБО, ИНК. (JP) Устройство ионтофореза стержневого типа
JP2009509659A (ja) * 2005-09-30 2009-03-12 Ｔｔｉ・エルビュー株式会社 生体界面への活性物質の送達のイオントフォレーシス装置及び方法
US8541177B2 (en) 2006-01-13 2013-09-24 A Chan Holding B.V. Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
DOP2007000015A (es) 2006-01-20 2007-08-31 Quark Biotech Inc Usos terapéuticos de inhibidores de rtp801
US20080077076A1 (en) * 2006-08-29 2008-03-27 Transcutaneous Technologies Inc. Iontophoresis device and method for operation with a usb (universal serial bus) power source
US20080260678A1 (en) * 2006-10-10 2008-10-23 University Of Colorado Molecular band-aid
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
JP5383497B2 (ja) * 2006-12-01 2014-01-08 Ｔｔｉ・エルビュー株式会社 装置、例として経皮送達装置に給電し且つ／又は当該装置を制御するシステム及び装置
US8197844B2 (en) 2007-06-08 2012-06-12 Activatek, Inc. Active electrode for transdermal medicament administration
US8729121B2 (en) 2007-06-25 2014-05-20 Adhezion Biomedical, Llc Curing accelerator and method of making
WO2009001359A2 (fr) 2007-06-27 2008-12-31 Quark Pharmaceuticals, Inc. Compositions et procédés d'inhibition de l'expression de gènes pro-apoptotiques
ES2454974T3 (es) * 2007-06-27 2014-04-14 The General Hospital Corporation Aparato para la inhibición óptica de la terapia fotodinámica
CN103898110A (zh) 2007-10-03 2014-07-02 夸克制药公司 新siRNA结构
EP2742875B1 (fr) 2007-11-14 2016-02-24 Adhezion Biomedical, LLC Adhésifs tissulaires cyanocarylates
US8862223B2 (en) 2008-01-18 2014-10-14 Activatek, Inc. Active transdermal medicament patch and circuit board for same
EP2106791A1 (fr) 2008-03-31 2009-10-07 Biotempt B.V. Glutamine ou dipeptide contenant de la glutamine avec une posologie spécifique pour le traitement des inflammations
US8293838B2 (en) 2008-06-20 2012-10-23 Adhezion Biomedical, Llc Stable and sterile tissue adhesive composition with a controlled high viscosity
US8198344B2 (en) 2008-06-20 2012-06-12 Adhezion Biomedical, Llc Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator
US20110117047A1 (en) 2008-06-23 2011-05-19 Adhezion Biomedical, Llc Cyanoacrylate tissue adhesives with desirable permeability and tensile strength
US8609128B2 (en) 2008-10-31 2013-12-17 Adhezion Biomedical, Llc Cyanoacrylate-based liquid microbial sealant drape
US8652510B2 (en) 2008-10-31 2014-02-18 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US9254133B2 (en) 2008-10-31 2016-02-09 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US20110288155A1 (en) 2008-12-18 2011-11-24 Elena Feinstein Sirna compounds and methods of use thereof
JP2012522005A (ja) 2009-03-26 2012-09-20 ヘンリー フォード ヘルス システム 神経損傷および神経変性疾患後の神経学的転帰を改善する方法
DK3276004T3 (da) 2009-06-08 2020-04-06 Quark Pharmaceuticals Inc Fremgangsmåder til behandling af kronisk nyresygdom
JP2013511990A (ja) 2009-11-26 2013-04-11 クォーク ファーマシューティカルズ インコーポレーティッド 末端置換を含むｓｉＲＮＡ化合物
TWI465238B (zh) 2009-12-09 2014-12-21 Nitto Denko Corp Ｈｓｐ４７表現之調節
US8778904B2 (en) 2009-12-09 2014-07-15 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the CNS
WO2011084193A1 (fr) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Composés oligonucléotidique comportant des extrémités sortantes non nucléotidiques
EP2538951B1 (fr) 2010-02-22 2020-04-22 Health Enhancement Products Inc. Agents et mécanismes de traitement pour la prévention de l'hypercholestérolémie
US9309019B2 (en) 2010-05-21 2016-04-12 Adhezion Biomedical, Llc Low dose gamma sterilization of liquid adhesives
WO2011163436A1 (fr) 2010-06-24 2011-12-29 Quark Pharmaceuticals, Inc. Composés à base d'arn double brin pour le gène rhoa et leur utilisation
US20140134231A1 (en) 2010-10-11 2014-05-15 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
CN103298939A (zh) 2010-12-06 2013-09-11 夸克医药公司 包含位置修饰的双链寡核苷酸化合物
WO2012118910A2 (fr) 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Compositions et procédés pour traiter des maladies et des lésions pulmonaires
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway
JP6132775B2 (ja) 2011-03-03 2017-05-24 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｔｏｌｌ様受容体経路のオリゴヌクレオチド修飾因子
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP2776565A1 (fr) 2011-11-08 2014-09-17 Quark Pharmaceuticals, Inc. Méthodes et compositions destinées à traiter des maladies, des troubles ou une lésion du système nerveux
EP2797632A1 (fr) 2012-01-01 2014-11-05 QBI Enterprises Ltd. Particules ciblant endo180 pour l'administration sélective d'agents thérapeutiques et diagnostiques
KR20140111673A (ko) 2012-01-12 2014-09-19 쿠아크 파마수티칼스 인코퍼레이티드 청력 및 균형 장애를 치료하기 위한 조합요법
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
HRP20170673T1 (hr) 2012-06-04 2017-07-14 Diamedica Inc. Glikozilacijske izoforme kalikreina 1 iz ljudskog tkiva
US9421245B2 (en) 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
DK2895608T3 (en) 2012-09-12 2019-01-21 Quark Pharmaceuticals Inc DOUBLE-STRENGTHED OIGONUCLEOTIDE MOLECULES FOR P53 AND PROCEDURES FOR USING IT
US9611473B2 (en) 2012-09-12 2017-04-04 Quark Pharmaceuticals, Inc. Double-stranded nucleic acid compounds
ES2872349T3 (es) 2012-09-12 2021-11-02 Quark Pharmaceuticals Inc Moléculas de oligonucleótidos bicatenarios para DDIT4 y métodos de uso de las mismas
BR112015015258A2 (pt) 2012-12-24 2017-09-26 Neurogastrx Inc métodos para tratar distúrbios do trato gastrintestinal
HK1222331A1 (zh) 2013-03-12 2017-06-30 通用医疗公司 修饰的缪勒抑制物质(mis)蛋白及其用於疾病治疗的用途
WO2014201372A1 (fr) 2013-06-13 2014-12-18 Health Enhancement Products, Inc. Composés et procédés pour affecter la sécrétion des cytokines
WO2015020960A1 (fr) 2013-08-09 2015-02-12 Novartis Ag Nouveaux polynucléotides longs arn non codants (arn lnc)
ES2912283T3 (es) 2013-12-11 2022-05-25 Massachusetts Gen Hospital Uso de proteínas de tipo sustancia inhibidora mülleriana (SIM) para la anticoncepción y conservación de la reserva ovárica
US9421297B2 (en) 2014-04-02 2016-08-23 Adhezion Biomedical, Llc Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
CN104353183B (zh) * 2014-10-31 2016-12-07 厦门微科格瑞生物科技有限公司 电解液位置固定的可佩戴智能药物导入结构
WO2016133922A1 (fr) 2015-02-16 2016-08-25 Zivo Bioscience, Inc. Procédés de modulation de réponses immunitaires et inflammatoires par le biais de l'administration d'une biomasse algale
CN109414053A (zh) 2016-02-16 2019-03-01 齐沃生物科学股份有限公司 经由给予源自藻类的补充物的动物营养支持
KR20250006907A (ko) 2017-03-09 2025-01-13 다이어메디카 인코포레이티드 조직 칼리크레인 1의 투약 형태
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
EP3922720A1 (fr) 2020-06-09 2021-12-15 Universidad de Murcia Thérapie pour empêcher un remodelage cardiaque indésirable après un infarctus aigu du myocarde
US20220265582A1 (en) 2021-02-24 2022-08-25 Universitätsspital Basel Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
US11801256B2 (en) 2021-06-08 2023-10-31 Universitätsspital Basel Antidepressant-psilocybin co-treatment to assist psychotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0276587A2 (fr) * 1986-12-05 1988-08-03 Raymond Bontemps Dispositif destiné au transfert sous cutané de substances médicinales
EP0278474A1 (fr) * 1987-02-10 1988-08-17 Drug Delivery Systems Inc. Diffusion électrolytique transdermique des polypeptides

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991755A (en) * 1973-07-27 1976-11-16 Medicon, Inc. Iontophoresis apparatus for applying local anesthetics
US4767401A (en) * 1975-04-22 1988-08-30 Maurice Seiderman Iontophoretic administration of ionizable or polar medicaments to a mammalian body
US4141359A (en) * 1976-08-16 1979-02-27 University Of Utah Epidermal iontophoresis device
US4250878A (en) * 1978-11-22 1981-02-17 Motion Control, Inc. Non-invasive chemical species delivery apparatus and method
CA1153427A (fr) * 1978-12-11 1983-09-06 Patrick T. Cahalan Electrode auto-collable
WO1981000964A1 (fr) * 1979-10-10 1981-04-16 Cyclotech Med Ind Bandage inhibant la douleur
US4382529A (en) * 1980-12-15 1983-05-10 Drdlik Frank J Sanitary dispensing closure
JPS5810066A (ja) * 1981-07-10 1983-01-20 株式会社アドバンス イオントフオレ−ゼ用プラスタ−構造体
US4919648A (en) * 1983-08-18 1990-04-24 Drug Delivery Systems Inc. High tack drug patch
CA1262564A (fr) * 1983-09-01 1989-10-31 Minoru Sasaki Dispositif d'iontophorese
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4702732A (en) * 1984-12-24 1987-10-27 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands
US4809707A (en) * 1985-04-12 1989-03-07 Kvm Engineering, Inc. Electrode for non-invasive allergy testing
US4722726A (en) * 1986-02-12 1988-02-02 Key Pharmaceuticals, Inc. Method and apparatus for iontophoretic drug delivery
US4786277A (en) * 1986-11-21 1988-11-22 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation
US4940456A (en) * 1987-02-10 1990-07-10 Dan Sibalis Electrolytic transdermal delivery of proteins
US4931046A (en) * 1987-05-15 1990-06-05 Newman Martin H Iontophoresis drug delivery system
US4942883A (en) * 1987-09-29 1990-07-24 Newman Martin H Drug delivery device

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0276587A2 (fr) * 1986-12-05 1988-08-03 Raymond Bontemps Dispositif destiné au transfert sous cutané de substances médicinales
EP0278474A1 (fr) * 1987-02-10 1988-08-17 Drug Delivery Systems Inc. Diffusion électrolytique transdermique des polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Proceedings of the Eleventh Annual Northeast Bioengineering Conference, March 14,15,1985, Worcester, Massachusetts, US, R.R. Burnette: "Transdermal transport enhancement by the use of iontophoresis", pages 45-47 *
Research Disclosure, November 1988, IEEE, see page 856, abstract 29520 G.A. lattin: "Method to control delivery of uncharged drugs via iontophoresis", *

Also Published As

Publication number Publication date
ZA909893B (en) 1991-09-25
IE904437A1 (en) 1991-06-19
PT96151A (pt) 1991-09-30
WO1991008795A2 (fr) 1991-06-27
AU6972591A (en) 1991-07-18
US5167616A (en) 1992-12-01
CA2031873A1 (fr) 1991-06-15

Similar Documents

Publication Publication Date Title
WO1991008795A3 (fr) Procede ameliore d'administration d'un medicament par iontophorese
US5403275A (en) Method for reducing sensation in iontophoretic drug delivery
US5995869A (en) Reduction of skin sensitization in electrotransport drug delivery
US7212853B1 (en) Electrotransport agent delivery method and apparatus
US5697896A (en) Electrotransport delivery device
IE83316B1 (en) Device for reducing sensation during iontophoretic drug delivery
EP0195643A3 (en) Compositions and method of controlling transdermal penetration of topical and systemic agents
CA2064687A1 (fr) Methode et appareil pour l'administration transdermique de dexmedetomidine
EP0748638A3 (fr) Dispositif implantable de stimulation cardiaque
ATE165983T1 (de) Reduktion von hautirritationen und hautwiderstand während einer iontophoresebehandlung
CA2218369A1 (fr) Administration transdermique par electrotransport de fentanyl et de sufentanil
IE46069L (en) Adhesive skin patch
CA2044791A1 (fr) Ionophorese myocardique
IE790030L (en) Iontophoretic treatment.
CA2613061A1 (fr) Dispositif d'administration par electrotransport transdermique de fentanyl et de sufentanil
DE69829281D1 (de) Implantierbarer dreiphasenwellenformdefibrillator
WO1994017792A3 (fr) Compositions et procedes d'administration transdermique de medicaments
US5985316A (en) Composition and method of enhancing electrotransport agent delivery
GR3018883T3 (en) Use of specific fatty acids in the manufacture of a medicament for their Iontophoresis delivery
NZ218616A (en) Therapeutic skin patches for transdermal administration of 4,5,7,8-tetrahydro-6h-thiazolo(or oxazolo)(5,4-3)-azepines
EP0175440A3 (fr) Procédé de traitement de maux de tête dus à la migraine
NZ502405A (en) Transdermal therapy system (tts) for releasing an active agent into an organism through the skin and method for applying said transdermal therapy system to the skin
US7572252B1 (en) Electrotransport agent delivery method and apparatus
CA2060994A1 (fr) Appareil electrique servant a donner des medicaments transdermiques muni d'un dispositif de neutralisation, et methode de transfusion des medicaments
IT8419169A0 (it) Apparecchiatura elettronica ad impulsi per la stimolazione neuromuscolare, particolarmente adatta per impieghi nella terapia dei dolori muscolari ed in campo stomatologico.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE